On The Pen GLP-1 News30 Apr 2024

On The Pen: The Weekly Dose 4/30/24

1.7 mg of Wegovy is no longer in shortage:
Semaglutide: FDA website updated to show 1.7 mg of Wegovy is no longer in shortage
Link: https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Semaglutide%20Injection&st=c

GNC introduces special section for GLP-1 users:
GNC will have special section for GLP-1 users that will concentrate on four areas: GI Health, Retaining Lean muscle mass, Bone health, Nutritional support
Link: https://www.gnc.com/learn/newsroom/gnc-semaglutide-support-program.html

Identified upper dose values in tirzepatide high-dose trial
20 mg and 25 mg
Primary Completion in this trial is 12/24/2024 (Merry Christmas) with final completion September 30, 2025
Link: https://www.onthepen.com/post/higher-doses-of-zepbound-and-mounjaro-being-tested

US Senator Bernie Sanders investigating the price of Wegovy/Ozempic
Ozempic costs $936 per month, while Wegovy costs $1,350
Ozempic costs $155 in Canada, and cost $59 in Germany. This dramatic difference in cost has led to concerns about the accessibility and affordability of these drugs for American patients.
With the cardiovascular disease indication, millions of additional medicare patients are eligible for taking Wegovy which means billions at the current prices
Link: https://www.onthepen.com/post/the-price-of-health-bernie-sanders-investigates-ozempic-and-wegovy
Link: https://www.kff.org/medicare/issue-brief/a-new-use-for-wegovy-opens-the-door-to-medicare-coverage-for-millions-of-people-with-obesity/

Germany is promoting their pharmaceuticals industry:
tax breaks, and speeding up clinical trials
Eli Lilly is investing 2.3 Billion Euros to build a glp-1 manufacturing plant in Germany:
Link: https://uk.finance.yahoo.com/news/scholz-promises-support-pharma-sector-101833297.html

Lexaria begins phase 1 trial:
Lexaria (stock symbol: LEXX) will test their technology to improve stomach absorption of Rybelsus in phase 1 trial (i.e. wouldn't need large 25/50 mg doses if absorption was better).
They are also testing under tongue (sublingual) absorption of Rybelsus in another phase 1 trial
Link: https://ir.lexariabioscience.com/news-events/press-releases/detail/246/lexaria-receives-ethics-review-board-approval-to-begin-new

Viking Therapeutics earnings call
Planning to start addition phase 2 trial of injectable VikingTide (VK2735) in Q4 of 2024 that will l

Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!

🤝 Visit Our Sponsors!
OTPLinks.com

Decoding GLP-1 Book
Decoding GLP-1: A Guide for Friends and Family of Those On The Pen
Buy Here: https://amzn.to/3Dc66d4

MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT:
Venmo: OnThePen
Ca$h App: ManOnMounjaro

BECOME A MEMBER:
https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join

👉 My Amazon Affiliate Store:
https://www.amazon.com/shop/manonthemounjaroonthepen

WATCH MORE!
📺 We're Live M/W/F at 11 central: onthepen.tv

📲 Contact Me: dave@onthepen.com

Thank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit onthepen.com.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(198)

Compound GLP-1 Poll STUNS THE INTERNET!

What If We've Been Asking the Wrong Question?Patients say compounded GLP-1s are more effective than branded medications. Dave explains why the answer may have nothing to do with the drug itself, and e...

8 Jul 15min

How To Get $50 GLP-1

Millions of Medicare beneficiaries are about to gain access to GLP-1 weight loss medications for as little as $50 per month through the new Medicare Bridge Program, launching July 1. In this episode o...

23 Jun 44min

What Comes After Zepbound? The Biggest ADA 2026 Obesity Drug Breakthroughs

ADA 2026 delivered a massive wave of obesity and diabetes data, and in this episode of On The Pen, Dave Knapp (@manonthemounjaro) sits down with Jen (@JcanNuSH) ⁠ to break down the molecules, clinica...

16 Jun 1h 15min

Retatrutide Just Reached Bariatric Surgery Results

Dave sits down with nurse practitioner and former Retatrutide clinical trial participant David White to break down the biggest obesity headlines from the 2026 American Diabetes Association Conference....

11 Jun 48min

Retatrutide Before FDA Approval? Lilly Just Changed the Conversation

Dave breaks down an unreported Expanded Access Pathway that Eli Lilly has quietly established for Retatrutide.

9 Jun 20min

Eli Lilly Isn’t Telling Us About Their Future Obesity Drugs

Does Eli Lilly already have the solve for obesity? In this episode of On the Pen — the Weekly Dose Podcast, host Dave Knapp breaks down a stunning comment from Lilly's Chief Scientific Officer Daniel ...

2 Jun 20min